Drug repurposing for a defined disease mechanism

Candidate molecules nominated to treat fibrosis are typically tested in cell culture at nominal concentrations between 1 µM and 10 µM. In the human bloodstream, however, oral drugs often produce unbound steady-state plasma concentrations of only 10 nM to 500 nM, and compounds with 98% to 99.5% protein binding deliver far less free molecule to tissues. When a drug requires 10 µM to reverse a cellular phenotype but reaches only 100 nM of unbound exposure at its approved dose, the margin is 0.01. Published repurposing lists match disease mechanisms to off-patent compounds across timelines of 3 to 12 years, yet roughly 75% of rare-disease repurposing filings originate from small organisations that cannot fund clinical trials without knowing whether a compound can work at its approved label dose.

Computational and transcriptomic screens nominate dozens of approved compounds by reporting a single nominal active concentration in culture medium. What remains unmeasured is how much of that nominal concentration is lost to serum protein binding in the broth, plastic adsorption on microplate walls, and membrane retention inside cells. For 28 approved or clinical-stage compounds nominated to reverse TGF-β1-driven fibroblast-to-myofibroblast transitions, no dataset pairs phenotypic reversal potency with direct free-concentration corrections measured in the same medium and plateware lot. Without rapid equilibrium dialysis and endpoint mass-balance recovery, investigators cannot separate target engagement from physical depletion, nor determine what proportion of nominated molecules remains active below label-dose unbound exposures.

The Drug repurposing for a defined disease mechanism Apodex Lab cultures primary adult human lung fibroblasts from three unrelated donors stimulated with recombinant human TGF-β1 at 2 ng/mL for 72 hours at 37 °C and 5% carbon dioxide. Using high-content fluorescence imaging of α-smooth-muscle-actin stress fibres alongside liquid chromatography with tandem mass spectrometry, the lab delivers the median nominal-to-free potency inflation factor and the fraction of the 28-compound list that retains activity at label-dose unbound exposure. If compounds with medium unbound fractions below 1% and cell-associated fractions below 5% show halved survival rates, sponsors can eliminate high-loss candidates through benchtop physicochemical assays before committing resources to phenotypic confirmation.